Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipated in H2 2023. Press release BOSTON —. | March 28, 2023
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical. | March 24, 2023